Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.
Also called NCT07898709
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 100 participants
- Sponsor
- Al-Azhar University
- Registry
-
NCT07898709
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Egypt
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07898709. Randomized; no masking; primary purpose treatment. Start 2027-01 (anticipated); primary completion 2027-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
- Condition
- No Reflow Phenomenon
- Condition
- Reperfusion Injuries, Myocardial
- Condition
- Myocardial Infarction
- Condition
- STEMI - ST Elevation Myocardial Infarction
- Condition
- Sodium Glucose Co-Transporter 2 Inhibitors
- Condition
- Empagliflozin
- Condition
- Dapagliflozin
- Intervention (Drug)
- Empagliflozin (SGLT2i)
- Intervention (Drug)
- dapagliflozin
- Intervention (Drug)
- Standard medical treatment
- Lead sponsor
- Al-Azhar University
Record details
- Record id
cardio:ct-nct07898709- Content hash
f04ac6902189463b921a94f1f78ef5b8cfdc75ee1fb7578825090d3c781e8422